Brief: Volition Signs First Human Out Licensing Deal
09/09/2025 13:57
Sept 9 (Reuters) - VolitionRX Ltd VNRX.A: VOLITIONRX: SIGNS RESEARCH LICENSE & EXCLUSIVE COMMERCIAL OPTION RIGHTS AGREEMENT FOR APS WITH WERFEN'S IMMUNOASSAY TECHNOLOGY CENTER VOLITIONRX LTD: FULL TERMS OF AGREEMENT ARE CONFIDENTIAL Source text: ID:nPn6Pf6n7a Further company coverage: VNRX.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on VolitionRX
See all newsBrief: Volitionrx -Files Preliminary Prospectus For 10,006,360 Shares Of Common Stock Offered By Selling Stockholder - SEC Filing
Brief: Volitionrx - Advances Nu.Q Nets Platform Towards Commercialization
Brief: VolitionRX Limited Announces First Quarter 2026 Financial Results
Brief: Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna
Brief: Volition Announces First Ever Automated Nu.Q® Vet Cancer Test With Fujifilm Vet Systems